North America Liver Cancer Diagnostics Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
 Período de pronóstico |
2023 –2030 |
 Tamaño del mercado (año base) |
USD 4,031.47 Million |
 Tamaño del mercado (año de pronóstico) |
USD 6,707.57 Million |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
North America Liver Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Genomic Test, and Others), Cancer Stages (Stage 0, Stage I , Stage II, Stage III, and Stage IV), Cancer Type (Primary Liver Cancer and Secondary Liver Cancer), Product (Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), Gender (Female and Male), End-User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2030.
North America Liver Cancer Diagnostics Market Analysis and Insights
North America liver cancer diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The growing demand for better quality healthcare for liver cancer and rising preference for preventative health checkups is expected to boost the market’s growth.
North America liver cancer diagnostics market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.6% in the forecast period of 2023 to 2030 and is expected to reach USD 6,707.57 Million by 2030 from USD 4,031.47 Million in 2022.
North America liver cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for the safe distribution of machine and drug products are the major drivers which propelled the demand of the market in the forecast period.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
By Test Type (Imaging, Biopsy, Genomic Test, and Others), Cancer Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Cancer Type(Primary Liver Cancer and Secondary Liver Cancer), Product (Platform-Based Products, Instrument based products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), Gender (Female and Male), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) |
|
Countries Covered |
U.S., Canada, Mexico |
|
Market Players Covered |
Siemens Healthcare GmbH (Germany), Koninklijke Philips N.V.(Netherland), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), Epigenomics AG (Germany), Thermo Fisher Scientific Inc. (U.S.), QIAGEN(U.S.), F. Hoffmann-La Roche Ltd(Switzerland), Diagnostic Biosystems Inc. (U.S.), FUJIFILM Corporation (Japan), BD(U.S.), MOLGEN (Netherlands), BIOCEPT, INC. (U.S.), Sysmex Corporation (Japan), Elabscience Biotechnology Inc. (U.S.), Hipro Biotechnology Co., Ltd. (China), Altogen Biosystems (U.S.), ABK Biomedical Inc.(Canada), Diazyme Laboratories, Inc. (U.S.), and AB Sciex Pte Ltd. (Subsidiary of Danaher) (U.S.) among others |
Market Definition
Liver cancer diagnostics refers to the various methods and techniques used to detect and diagnose liver cancer. This may include laboratory tests, imaging tests, and physical examinations.
The liver cancer diagnostic market includes a wide range of products and services from various companies, including diagnostic laboratories, medical device manufacturers, and pharmaceutical companies. The market is driven by the increasing incidence of liver cancer and the growing demand for accurate and reliable diagnostic tests.
North America Liver Cancer Diagnostics Market Dynamics
Drivers
-
Unmet need for non-invasive, accurate, and reliable diagnostic tests for earlier cancer detection
Diagnostics is also becoming an increasingly important tool for converting the most recent developments in basic research into better clinical outcomes for patients. The development of novel, quick, sensitive, less invasive, and more accurate molecular diagnostic tests is being accelerated by some of the most exciting scientific developments of the time, including genomics, proteomics, and other "omics" technologies. This significantly impacts the ability to identify and treat different cancers earlier and more precisely. By customizing medicines based on each patient's distinct molecular profile, diagnostics help doctors make better-educated treatment decisions.
Thus, the unmet need for non-invasive, accurate, and reliable diagnostic tests for earlier cancer detection demands is expected to drive the market's growth.
-
Increasing early diagnosis of liver cancer
Machine learning could revolutionize early cancer diagnosis, which trains computers to see patterns in complex data. Tools include assessments of common health data, medical imaging, biopsy samples, and blood tests to help in early diagnosis and risk stratification. In many tumor types, the likelihood of undergoing successful therapy increases with an early cancer diagnosis. One important strategy is to assess patients at risk who do not exhibit symptoms and respond quickly and appropriately to those who do.
Thus, earlier detection improves treatment options, patient outcomes, and survival and is expected to drive the growth of the North America liver cancer diagnostics market.
Restraint
-
Barriers to liver cancer diagnosis and poor prognosis
Cancer is the leading cause of death in developed and developing countries. Cancer mortality is expected to rise to an estimated 13.1 million deaths annually by 2030. However, certain types of cancer have a high chance of being cured if they are detected at an early stage and adequately treated. The delays in cancer diagnosis may occur throughout the diagnostic pathway: patient, primary care, and secondary care. Patient delays may occur when the patient fails to recognize and act on suspicious cancer symptoms. Poor public awareness of early cancer symptoms is considered the predominant reason for delayed presentation, particularly if symptoms are atypical in nature.
The late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the growth of the North America liver cancer diagnostics market.
Opportunity
-
Increasing awareness towards liver cancer
Liver cancer awareness is a chance to increase knowledge about these diseases and to put the spotlight on research into their causes, prevention, diagnosis, treatment, and survival. The objective is to assist persons who have been impacted by the liver and to promote healthy habits. Primary liver cancer is the name for cancer that develops in the liver. Hepatocellular carcinoma is the most prevalent type of primary liver cancer in adults (HCC). The third most common cause of cancer-related fatalities worldwide is this particular form of liver cancer. About 25,000 men and 11,000 women are diagnosed with liver cancer each year in the US, and the illness claims the lives of 19,000 men and 9,000 women.
Thus, government initiatives toward liver cancer diagnostics is expected to create an opportunity for the growth of the market.
Challenge
- Strict regulations for the approval of liver cancer diagnostic products
The strict guidelines for product approval and market commercialization are proving to be a major obstacle for manufacturers of cancer diagnostic products worldwide. Every nation has its own regulations and employs a different regulating body.
The players involved in the production and marketing of medical devices must adjust as a result of the strict regulations. This would affect all stakeholders globally, which is projected to challenge the market throughout the forecast period. Thus, it is expected to act as a challenge for the North America liver cancer diagnostics market to hamper its growth.
Recent Development
- In December 2022, FUJIFILM Holdings America Corporation announced the company has a purchase agreement asset with Inspirata, Inc. to acquire a digital pathology business to expand its robust enterprise imaging offering. This results in enabling the integration of pathology images and data into a healthcare organization’s electronic health record system to streamline care delivery for oncology patients
North America Liver Cancer Diagnostics Market Scope
North America liver cancer diagnostics market is categorized into nine notable segments, which are test type, cancer type, cancer stages, product, application, technology, gender, end-user, and distribution channels.
By Test Type
- Imaging Test
- Biopsy
- Genomic Test
- Others
By Cancer Stages
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
By Cancer Type
- Primary Liver Cancer
- Secondary Liver Cancer
By Product
- Platform-Based Products
- Instrument-Based Products
- Kits and Reagents
- Other Consumables
By Technology
- Fluorescent in Situ Hybridization
- Next Generation Sequencing
- Fluoroimmunoassay
- Comparative Genomic Hybridization
- Immunohistochemical
- Others
By Application
- Screening
- Diagnostic and Predictive
- Prognostic
- Research
By Gender
- Female
- Male
By End-User
- Hospitals
- Cancer Research Centers
- Academic Institutes
- Diagnostic Centers
- Ambulatory Surgical Centers
- Others
By Distribution Channel
- Direct Tenders
- Retail Sales
- Others
North America Liver Cancer Diagnostics Market Regional Analysis/Insights
North America liver cancer diagnostics market is segmented into nine notable segments based on test type, cancer stages, cancer type, product, application, technology, gender, end-user, and distribution channel.
The countries covered in this market report are the U.S., Canada, and Mexico.
The U.S. is dominating due to the presence of key market players in the largest consumer market with high GDP.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Liver Cancer Diagnostics Market Share Analysis
North America liver cancer diagnostics market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the North America Liver cancer diagnostics market.
Some of the major players operating in the North America liver cancer diagnostics market are Siemens Healthcare GmbH (Germany), Koninklijke Philips N.V.(Netherland), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), Epigenomics AG (Germany), Thermo Fisher Scientific Inc. (U.S.), QIAGEN(U.S.), F. Hoffmann-La Roche Ltd(Switzerland), Diagnostic Biosystems Inc. (U.S.), FUJIFILM Corporation (Japan), BD(U.S.), MOLGEN (Netherlands), BIOCEPT, INC. (U.S.), Sysmex Corporation (Japan), Elabscience Biotechnology Inc. (U.S.), Hipro Biotechnology Co., Ltd. (China), Altogen Biosystems (U.S.), ABK Biomedical Inc.(Canada), Diazyme Laboratories, Inc. (U.S.), AB Sciex Pte Ltd. (Subsidary of Danaher) (U.S.) among others.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TEST TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE ANALYSIS
4.2 PORTER ANALYSIS
4.3 EPIDEMIOLOGY
5 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS
6 INDUSTRY INSIGHTS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION
7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER
7.1.3 INCREASING CASES OF LIVER CANCER
7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS
7.2 RESTRAINTS
7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS
7.3 OPPORTUNITIES
7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER
7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE
7.4 CHALLENGES
7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE
8 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 IMAGING TEST
8.2.1 MAGNETIC RESONANCE IMAGING (MRI)
8.2.1.1 MR ANGIOGRAPHY (MRA)
8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY
8.2.2 COMPUTED TOMOGRAPHY
8.2.3 POSITRON EMISSION TOMOGRAPHY
8.2.4 ULTRASOUND
8.2.5 OTHERS
8.3 GENOMIC TEST
8.4 BIOPSY
8.4.1 FINE NEEDLE ASPIRATION BIOPSY
8.4.2 CORE NEEDLE BIOPSY
8.4.3 LAPAROSCOPY
8.5 OTHERS
9 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE
9.1 OVERVIEW
9.2 STAGE III
9.3 STAGE II
9.4 STAGE IV
9.5 STAGE I
9.6 STAGE 0
10 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 SECONDARY LIVER CANCER
10.2.1 HEMANGIOMA
10.2.2 HEPATIC ADENOMA
10.2.3 FOCAL NODULAR HYPERPLASIA
10.3 PRIMARY LIVER CANCER
10.3.1 HEPATOCELLULAR CARCINOMA (HCC)
10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER)
10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA
10.3.4 HEPATOBLASTOMA
11 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT
11.1 OVERVIEW
11.2 PLATFORM BASED PRODUCTS
11.2.1 NEXT GENERATION SEQUENCING
11.2.2 MICROARRAYS
11.2.3 PCR
11.2.4 OTHERS
11.3 INSTRUMENT BASED PRODUCTS
11.3.1 IMAGING
11.3.2 BIOPSY
11.4 KITS AND REAGENTS
11.4.1 ELISA TEST KITS
11.4.2 CASSETTE TEST KITS
11.4.3 OTHERS
11.5 OTHER CONSUMABLES
12 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 SCREENING
12.2.1 PLATFORM BASED PRODUCTS
12.2.2 INSTRUMENT BASED PRODUCTS
12.2.3 KITS AND REAGENTS
12.2.4 OTHER CONSUMABLES
12.3 DIAGNOSTIC AND PREDICTIVE
12.3.1 PLATFORM BASED PRODUCTS
12.3.2 INSTRUMENT BASED PRODUCTS
12.3.3 KITS AND REAGENTS
12.3.4 OTHER CONSUMABLES
12.4 PROGNOSTIC
12.4.1 PLATFORM BASED PRODUCTS
12.4.2 INSTRUMENT BASED PRODUCTS
12.4.3 KITS AND REAGENTS
12.4.4 OTHER CONSUMABLES
12.5 RESEARCH
12.5.1 PLATFORM BASED PRODUCTS
12.5.2 INSTRUMENT BASED PRODUCTS
12.5.3 KITS AND REAGENTS
12.5.4 OTHER CONSUMABLES
13 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
13.1 OVERVIEW
13.2 FLUORESCENT IN SITU HYBRIDIZATION
13.3 NEXT GENERATION SEQUENCING
13.4 FLUORIMMUNOASSAY
13.5 COMPARATIVE GENOMIC HYBRIDIZATION
13.6 IMMUNOHISTOCHEMICAL
13.7 OTHERS
14 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER
14.1 OVERVIEW
14.2 MALE
14.3 FEMALE
15 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 DIAGNOSTIC CENTERS
15.4 CANCER RESEARCH CENTERS
15.5 AMBULATORY SURGICAL CENTERS
15.6 ACADEMIC INSTITUTES
15.7 OTHERS
16 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.4 OTHERS
17 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY REGION
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
17.1.3 MEXICO
18 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 F. HOFFMANN-LA ROCHE LTD.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.2 KONINLIJKE PHILIPS N.V.
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 THERMO FISHER SCIENTIFIC INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 BD
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 SIEMENS HEALTHCARE GMBH
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENT
20.6 AGILENT TECHNOLOGIES, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 ABK BIOMEDICAL INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.)
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 ALTOGEN BIOSYSTEMS
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT
20.1 BIOCEPT, INC.
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 BODITECH MED INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENTS
20.12 DIAGNOSTIC BIOSYSTEMS INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 DIAZYME LABORATORIES, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 ELABSCIENCE BIOTECHNOLOGY INC.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 EPIGENOMICS AG
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENT
20.16 FUJIFILM CORPORATION
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENT
20.17 FUJIREBIO
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENTS
20.18 HIPRO BIOTECHNOLOGY CO., LTD.
20.18.1 COMPANY SNAPSHOT
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENT
20.19 ILLUMINA, INC.
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENTS
20.2 MOLGEN
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENT
20.21 QIAGEN
20.21.1 COMPANY SNAPSHOT
20.21.2 REVENUE ANALYSIS
20.21.3 PRODUCT PORTFOLIO
20.21.4 RECENT DEVELOPMENT
20.22 Q-LINE BIOTECH PVT LTD.
20.22.1 COMPANY SNAPSHOT
20.22.2 PRODUCT PORTFOLIO
20.22.3 RECENT DEVELOPMENT
20.23 SYSMEX CORPORATION
20.23.1 COMPANY SNAPSHOT
20.23.2 REVENUE ANALYSIS
20.23.3 PRODUCT PORTFOLIO
20.23.4 RECENT DEVELOPMENT
20.24 TEBUBIO
20.24.1 COMPANY SNAPSHOT
20.24.2 PRODUCT PORTFOLIO
20.24.3 RECENT DEVELOPMENT
20.25 TOSOH INDIA PVT. LTD.
20.25.1 COMPANY SNAPSHOT
20.25.2 PRODUCT PORTFOLIO
20.25.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Lista de Tablas
TABLE 1 DIFFERENT TYPES OF CANCER NON-INVASIVE SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS
TABLE 2 LIVER CANCER RATES
TABLE 3 APPROVED DIAGNOSTICS OF LIVER CANCER
TABLE 4 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA IMAGING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA GENETIC TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA STAGE III IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA STAGE II IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA STAGE IV IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA STAGE I IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA STAGE 0 IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA OTHER CONSUMABLES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA NEXT GENERATION SEQUENCING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA FLUORIMMUNOASSAY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA IMMUNOHISTOCHEMICAL IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA MALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA FEMALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA HOSPITALS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA DIAGNOSTIC CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA CANCER RESEARCH CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA ACADEMIC INSTITUTES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA DIRECT TENDER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA RETAIL SALES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 76 NORTH AMERICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 78 NORTH AMERICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 NORTH AMERICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 81 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 83 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 U.S. IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 86 U.S. BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 88 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 89 U.S. SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 90 U.S. PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 91 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 92 U.S. PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 U.S. INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 U.S. KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 96 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 97 U.S. SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 98 U.S. DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 99 U.S. PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 100 U.S. RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 101 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 102 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 103 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 104 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 CANADA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 CANADA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 107 CANADA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 109 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 110 CANADA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 111 CANADA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 112 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 113 CANADA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 CANADA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 115 CANADA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 116 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 117 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 118 CANADA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 119 CANADA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 120 CANADA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 121 CANADA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 122 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 123 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 124 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 125 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 126 MEXICO IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 MEXICO MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 128 MEXICO BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 130 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 131 MEXICO SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 132 MEXICO PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 133 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 134 MEXICO PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 135 MEXICO INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 136 MEXICO KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 137 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 138 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 MEXICO SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 MEXICO DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 141 MEXICO PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 142 MEXICO RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 143 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 144 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 145 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
Lista de figuras
FIGURE 1 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF LIVER CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET
FIGURE 14 THE NORTH AMERICA MORTALITY RATE DUE TO CANCER
FIGURE 15 INCREASING NORTH AMERICA CANCER RATE IN 2020
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT
FIGURE 17 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 18 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 19 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 20 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2022
FIGURE 22 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION)
FIGURE 23 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030)
FIGURE 24 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 26 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 27 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 28 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 29 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022
FIGURE 30 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 31 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 32 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 33 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022
FIGURE 34 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 35 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 36 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 37 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022
FIGURE 38 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 39 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 40 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 41 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2022
FIGURE 42 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)
FIGURE 43 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 44 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 45 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 46 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 47 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 48 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 49 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 50 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 51 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 52 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 53 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 54 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 55 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 56 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 57 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 58 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
